Nu Med Plus Stock Market Value
| NUMD Stock | USD 0.02 0.00 0.00% |
| Symbol | Nu-Med |
Nu-Med Plus 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Nu-Med Plus' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Nu-Med Plus.
| 11/27/2025 |
| 02/25/2026 |
If you would invest 0.00 in Nu-Med Plus on November 27, 2025 and sell it all today you would earn a total of 0.00 from holding Nu Med Plus or generate 0.0% return on investment in Nu-Med Plus over 90 days. Nu-Med Plus is related to or competes with Talis Biomedical, USA Equities, and Kelyniam Global. Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of m... More
Nu-Med Plus Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Nu-Med Plus' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Nu Med Plus upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 72.68 | |||
| Value At Risk | (12.28) | |||
| Potential Upside | 0.4115 |
Nu-Med Plus Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nu-Med Plus' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Nu-Med Plus' standard deviation. In reality, there are many statistical measures that can use Nu-Med Plus historical prices to predict the future Nu-Med Plus' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (1.36) | |||
| Treynor Ratio | (0.62) |
Nu-Med Plus February 25, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.61) | |||
| Mean Deviation | 2.92 | |||
| Coefficient Of Variation | (2,269) | |||
| Standard Deviation | 8.32 | |||
| Variance | 69.2 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (1.36) | |||
| Treynor Ratio | (0.62) | |||
| Maximum Drawdown | 72.68 | |||
| Value At Risk | (12.28) | |||
| Potential Upside | 0.4115 | |||
| Skewness | 1.45 | |||
| Kurtosis | 15.11 |
Nu Med Plus Backtested Returns
Nu Med Plus retains Efficiency (Sharpe Ratio) of -0.0458, which conveys that the firm had a -0.0458 % return per unit of price deviation over the last 3 months. Nu-Med Plus exposes nineteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Nu-Med Plus' Mean Deviation of 2.92, information ratio of (0.06), and Market Risk Adjusted Performance of (0.61) to check out the risk estimate we provide. The company owns a Beta (Systematic Risk) of 0.6, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Nu-Med Plus' returns are expected to increase less than the market. However, during the bear market, the loss of holding Nu-Med Plus is expected to be smaller as well. At this point, Nu Med Plus has a negative expected return of -0.4%. Please make sure to verify Nu-Med Plus' variance, as well as the relationship between the value at risk and rate of daily change , to decide if Nu Med Plus performance from the past will be repeated at future time.
Auto-correlation | 0.90 |
Excellent predictability
Nu Med Plus has excellent predictability. Overlapping area represents the amount of predictability between Nu-Med Plus time series from 27th of November 2025 to 11th of January 2026 and 11th of January 2026 to 25th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Nu Med Plus price movement. The serial correlation of 0.9 indicates that approximately 90.0% of current Nu-Med Plus price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.9 | |
| Spearman Rank Test | 0.58 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Nu-Med OTC Stock
Nu-Med Plus financial ratios help investors to determine whether Nu-Med OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nu-Med with respect to the benefits of owning Nu-Med Plus security.